Cargando…

The Impact of Induction Regimes on Immune Responses in Patients with Multiple Myeloma

SIMPLE SUMMARY: Multiple myeloma remains an essentially incurable blood cancer. New patients with multiple myeloma are often treated with induction chemotherapy, stem cell transplantation, and then maintenance chemotherapy. As the immune system of the patient is a critical element in controlling the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Firer, Michael A., Shapira, Michael Y., Luboshits, Galia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8393868/ https://www.ncbi.nlm.nih.gov/pubmed/34439244 http://dx.doi.org/10.3390/cancers13164090

Ejemplares similares

Long-term survival without graft-versus-host-disease following infusion of allogeneic myeloma-specific Vβ T cell families
por: Yado, S., et al.
Publicado: (2019)

Gold nanoparticles stabilize peptide-drug-conjugates for sustained targeted drug delivery to cancer cells
por: Kalimuthu, Kalishwaralal, et al.
Publicado: (2018)

Boosting Immunity against Multiple Myeloma
por: Lopes, Raquel, et al.
Publicado: (2021)

The Cancer-Immunity Cycle in Multiple Myeloma
por: Casey, Mika, et al.
Publicado: (2021)

Novel panel of protein biomarkers to predict response to bortezomib-containing induction regimens in multiple myeloma patients
por: Ting, Kay Reen, et al.
Publicado: (2017)

Induction Treatment in Transplant-eligible Multiple Myeloma
por: Quinn, J., et al.
Publicado: (2021)

VAD chemotherapy as remission induction for multiple myeloma.
por: Anderson, H., et al.
Publicado: (1995)

Lenalidomide in the Treatment of Young Patients with Multiple Myeloma: From Induction to Consolidation/Maintenance Therapy
por: Lupo, Barbara, et al.
Publicado: (2012)

The Immune Microenvironment in Multiple Myeloma: Friend or Foe?
por: Lopes, Raquel, et al.
Publicado: (2021)

Harnessing the Immune System to Fight Multiple Myeloma
por: Krejcik, Jakub, et al.
Publicado: (2021)

Therapeutics to harness the immune microenvironment in multiple myeloma
por: Ignatz-Hoover, James J., et al.
Publicado: (2022)

Immune checkpoint inhibitors for multiple myeloma immunotherapy
por: Liu, Zhaoyun, et al.
Publicado: (2023)

Targeted drug delivery for cancer therapy: the other side of antibodies
por: Firer, Michael A, et al.
Publicado: (2012)

The Insider: Impact of the Gut Microbiota on Cancer Immunity and Response to Therapies in Multiple Myeloma
por: Brevi, Arianna, et al.
Publicado: (2022)

The Impact of Re-induction Prior to Salvage Autologous Stem Cell Transplantation in Multiple Myeloma
por: Miller, Kevin C., et al.
Publicado: (2019)

Curability of Multiple Myeloma
por: Alexanian, Raymond, et al.
Publicado: (2012)

Targeted Therapies for Multiple Myeloma
por: Leow, Christopher Chang-Yew, et al.
Publicado: (2021)

Immune-based therapies in the management of multiple myeloma
por: Zanwar, Saurabh, et al.
Publicado: (2020)

Elotuzumab for the treatment of multiple myeloma
por: Wang, Yucai, et al.
Publicado: (2016)

Risk and Response-Adapted Treatment in Multiple Myeloma
por: Cazaubiel, Titouan, et al.
Publicado: (2020)

Recent Innovations in Peptide Based Targeted Drug Delivery to Cancer Cells
por: Gilad, Yosi, et al.
Publicado: (2016)

Co-evolution of Immune Response in Multiple Myeloma: Implications for Immune Prevention
por: McCachren, Samuel S., et al.
Publicado: (2021)

Imaging findings of extraosseous multiple myeloma
por: Patlas, Michael, et al.
Publicado: (2015)

Multiple myeloma
por: Collins, Conor D.
Publicado: (2010)

Metabolic Vulnerabilities in Multiple Myeloma
por: Lim, Julia S. L., et al.
Publicado: (2022)

Clinical Considerations for Immunoparesis in Multiple Myeloma
por: Chahin, Michael, et al.
Publicado: (2022)

Severe impairment of T-cell responses to BNT162b2 immunization in patients with multiple myeloma
por: Enßle, Julius C., et al.
Publicado: (2022)

Impact of the time interval between end of induction and autologous hematopoietic transplantation in newly diagnosed patients with multiple myeloma
por: Charalampous, Charalampos, et al.
Publicado: (2022)

Impact of Clinical Parameters and Induction Regimens on Peripheral Blood Stem-Cell Mobilization and Collection in Multiple Myeloma Patients
por: Sauer, Sandra, et al.
Publicado: (2023)

Changes in uninvolved immunoglobulins during induction therapy for newly diagnosed multiple myeloma
por: Ravi, P, et al.
Publicado: (2017)

Induction Therapy and Stem Cell Mobilization in Patients with Newly Diagnosed Multiple Myeloma
por: Ria, Roberto, et al.
Publicado: (2012)

Association of response endpoints with survival outcomes in multiple myeloma
por: Lonial, S, et al.
Publicado: (2014)

Lenalidomide, bortezomib and dexamethasone induction therapy for the treatment of newly diagnosed multiple myeloma: a practical review
por: McCaughan, Georgia J., et al.
Publicado: (2022)

The frequency of T regulatory cells modulates the survival of multiple myeloma patients: detailed characterisation of immune status in multiple myeloma
por: Giannopoulos, K, et al.
Publicado: (2012)

Outcomes of patients with primary refractory multiple myeloma in the era of triplet and quadruplet induction therapy
por: Charalampous, Charalampos, et al.
Publicado: (2023)

Impact of hypoxia on the pathogenesis and therapy resistance in multiple myeloma
por: Ikeda, Sho, et al.
Publicado: (2021)

New Treatment Strategies Making an Impact in Multiple Myeloma
por: Gleason, Charise, et al.
Publicado: (2017)

Regulatory T-Cells and Multiple Myeloma: Implications in Tumor Immune Biology and Treatment
por: Hadjiaggelidou, Christina, et al.
Publicado: (2021)

Mechanisms of Immune Evasion in Multiple Myeloma: Open Questions and Therapeutic Opportunities
por: Botta, Cirino, et al.
Publicado: (2021)

Deciphering mechanisms of immune escape to inform immunotherapeutic strategies in multiple myeloma
por: Swamydas, Muthulekha, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ng2h8hllkhvfijpf76rtqjvbo7